BEAM Beam Therapeutics Inc.
BEAM Beam Therapeutics Inc.
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-10-16 1 bear converging
POC $27.37 · VWAP $28.07 · -16.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
2 watchlists
BEAM Price Structure
Loading timeframes…
Peers
Every watchlist BEAM belongs to, members best 30-day change first — BEAM highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
Reported the quarter ending 2026-06-30: revenue $490000, diluted EPS -$1.18, net income -$123M (SEC filing). Across the print the stock moved +4.5% (close before → first close after).
full note →Against street estimates
How BEAM's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about BEAM from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 25 days ago · Sep 22
- Press Releases | Beam Therapeutics
- Beam Therapeutics (BEAM) Earnings Date and Reports 2026
- Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD) | Beam Therapeutics
- Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
- Beam Therapeutics Inc (BEAM) Live Share Price, Invest From India
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
BEAM research tape
61 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.